Edit
Trevena
https://www.trevena.com/?portfolioCats=34,23,29,35,22,24,30,25,28,31#new_tabLast activity: 30.08.2021
Active
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions.
Investors 1
| Date | Name | Website |
| - | Vivo Capit... | vivocapita... |
Mentions in press and media 8
| Date | Title | Description |
| 30.08.2021 | Trevena : Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021 | CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, t... |
| 10.08.2021 | Trevena : Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy | CHESTERBROOK, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, tod... |
| 12.07.2021 | Trevena : Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research | Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical compan... |
| 12.05.2021 | TREVENA, INC. Trevena : Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting | -- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis -- CHESTERBROOK, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Trevena, ... |
| 06.05.2021 | TREVENA, INC. Trevena : Reports First Quarter 2021 Results | -- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and cognitive function TRV027 selected for two large, multi-site C... |
| 15.04.2021 | TREVENA, INC. Trevena : Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting | -- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical... |
| 02.11.2018 | Trevena hammered again as the FDA spurns their controversial pain drug — but AcelRx gets a green light | The FDA evidently managed to surprise the die-hard supporters of Trevena today by rejecting their controversial pain drug oliceridine — sending their shares $TRVN down 34% in a deep plunge into penny stock territory. Ac... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |